Prescription of psychotropic drugs to patients with schizophrenia: An Italian national survey

European Journal of Clinical Pharmacology

Volumn 60, Issue 7, 2004, Pages 513-522

  Magliano, Lorenza ^a   Fiorillo, Andrea ^a   Guarneri, Manuela ^a   Marasco, Cecilia ^a   De Rosa, Corrado ^a   Malangone, Claudio ^a   Maj, Mario ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DELORAZEPAM; DIAZEPAM; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; HYPNOTIC SEDATIVE AGENT; LORAZEPAM; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGE DISTRIBUTION; ANXIETY; DEMOGRAPHY; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG USE; EDUCATION; GEOGRAPHIC DISTRIBUTION; HEALTH SURVEY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; POLYPHARMACY; POPULATION DENSITY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SOCIOBIOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; DATA COLLECTION; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; ITALY; MALE; MENTAL HEALTH SERVICES; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; POLYPHARMACY; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA;

EID: 5344265099     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0803-7     Document Type: Review

References (59)

1. Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E (1979) Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 36:1283-1294
2. Schooler NR, Levine J, Severe JB, Brauzer B, DiMascio A, Klerman GL, Tuason VB (1980) Prevention of relapse in schizophrenia: an evaluation of fluphenazine decanoate. Arch Gen Psychiatry 37:16-24
3. American Psychiatric Association (1997) Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Press, Washington DC
4. Canadian Psychiatric Association (1998) Canadian clinical practice guidelines for the treatment of schizophrenia. Can J Psychiatry 43[Suppl 2]:255-405
5. Geddes J, Freemantle N, Harrison P, Bebbington P (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic review and meta-regression analysis. BMJ 321:1371-1376
6. National Institute for Clinical Excellence-NICE (2003) Schizophrenia - full national clinical guideline on core intervention in primary and secondary care. Gaskell Press and British Psychological Society, London
7. Johnson DA, Wright NF (1990) Drug prescribing for schizophrenic out-patients on depot injections. Repeat surveys over 18 years. Br J Psychiatry 156:827-834
8. Tibaldi G, Munizza C, Bollini P, Pirfo E, Punzo F, Gramaglia F (1997) Utilization of neuroleptic drugs in Italian mental health services: a survey in Piedmont. Psychiatr Serv 18:213-217
9. Ito C, Yubota Y, Sato M (1990) A prospective survey on drug choice for admitted patients with schizophrenia. Psychiatr Clin Neurosci 53[Suppl]:S35-S40
10. Tognoni G (1999) Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy: Italian collaborative study group on the outcome of severe mental disorders. Eur J Clin Pharmacol 55:685-690
11. Edwards S, Kumar V (1984) A survey of prescribing of psychotropic drugs in a Birmingham Psychiatric Hospital. Br J Psychiatry 145:502-507
12. Wilson WH, Ban TA, Guy W (1985) Pharmacotherapy of chronic hospitalised schizophrenics: prescription practices. Neuropsychobiology 14:75-82
13. Schmidt LG, Lammers V, Stockel M, Muller-Oerlinghausen B (1988) Recent trends in prescribing psychotropic drugs at a psychiatric university hospital (1981-1984). Pharmacopsychiatry 21:126-130
14. Keks NA, Altson K, Hope J, Krapivensky N, Culhane C, Tanaghow A, Doherty P, Bootle A (1999) Use of antipsychotics and adjunctive medications by an inner urban community psychiatric service. Aust NZJ Psychiatry 33:896-901
15. Schumacher JE, Makela EH, Griffin HR (2003) Multiple antipsychotic medication prescribing patterns. Ann Pharmacother 37:951-955
16. Chong SA, Remington GJ, Lee N, Mahendran R (2000) Contrasting clozapine prescribing patterns in the east and west? Ann Acad Med Singapore 29:75-78
17. Leslie DL, Rosenheck RA (2001) Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors. Med Care 39:907-909
18. Weiden PJ, Casey DE (1999) Polypharmacy combining antipsychotic medication in the treatment of schizophrenia. J Pract Psychiatry Behav Health 5:229-233
19. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N (2003) Combination antipsychotic therapy in clinical practice. Psychiatr Serv 54:55-59
20. Tempier RP, Pawliuk NH (2003) Conventional, atypical, and combination antipsychotic prescriptions: a 2-year comparison. J Clin Psychiatry 64:673-679
21. Williams CL, Johnstone BM, Kesterson JG, Yavor KA, Schmetzer AD (1999) Evaluation of antipsychotics and concomitance medication use patterns in patients with schizophrenia. Med Care 37[Suppl 4]:AS81-AS86
22. Brunot A, Lachaux B, Sontag H, Casadebaig F, Philippe A, Rouillon F, Clery-Melin P, Hergueta T, Llorca PM, Moreaudefarges T, Guillon P, Lebrun T (2002) Pharmaco-epidemiological study on antipsychotic drug prescription: in French psychiatry: patient characteristics, antipsychotic treatment and care management for schizophrenia. Encephale 28:129-138
23. Yip KC, Ungvari GS, Cheung HK, Ng FS, Lau ST (1997) A survey of antipsychotic treatment for schizophrenia in Hong Kong. Chin Med J 110:792-796
24. Sernyak MJ, Leslie D, Rosenheck R (2003) Use of system-wide outcomes monitoring data to compare the effectiveness of atypical neuroleptic medications. Am J Psychiatry 160:310-315
25. Brunette MF, Noordsy DL, Xie H, Drake RE (2003) Benzo-diazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatr Serv 54:1395-1401
26. Fourrier A, Gasquet I, Allicar MP, Bouhassira M, Lepine JP, Begaud B (2000) Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. Br J Clin Pharmacol 49:80-86
27. Lehman AF, Steinwachs DM, the Co-Investigators of the Port Project (1998) Translating research into practice: the schizophrenia patient outcomes research team (PORT) treatment recommendations. Schizophr Bull 24:1-10
28. Barbui C, Danese A, Guaiana G, Mapelli L, Miele L, Monzani E, Percudani M, on behalf of the study group (2002) Prescribing second-generation antipsychotics and the evolving standard of care in Italy. Pharmacopsychiatry 35:239-243
29. Covell NC, Jackson TC, Evans AC, Essock SM (2002) Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 22:17-29
30. Bollini P, Pampallona S, Orza MJ, Adams ME, Chalmers TC (1994) Antipsychotic drugs: is more worse? A meta-analysis of the published randomised control trials. Psychol Med 24:307-316
31. Sohler NL, Walkup J, McAlpine D, Boyer C, Olfson M (2003) Antipsychotic dosage at hospital discharge and outcomes among persons with schizophrenia. Psychiatr Serv 54:1258-1263
32. Muscettola G, Bollini P, Pampallona S (1991) Pattern of neuroleptic drug use in Italian Mental Health Service. DICP 25:296-301
33. Kuno E, Rothbard AB (2002) Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am J Psychiatry 159:567-572
34. Valenti AM, Narendran R, Pristach CA (2003) Who are patients on conventional antipsychotics? Schizophr Bull 29:195-199
35. Dewa CS, Remington G, Herrmann N, Fearnley J, Goering P (2002) How much are atypical antipsychotic agents being used, and they reach the populations who need them? A Canadian experience. Clin Ther 24:1466-1476
36. Ren XS, Kazis LE, Lee AF, Hamed A, Huang YH, Cunningham F, Miller DR (2002) Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia. J Clin Pharm Ther 27:441-451
37. Frangou S, Lewis M (2000) Atypical antipsychotics in ordinary clinical practice: a pharmaco-epidemiologic survey in a south London service. Eur Psychiatry 15:220-226
38. Citrome L, Levine J, Allingham B (1996) Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharmacol Bull 32:321-326
39. Adams CE, Fenton MKP, Quraishi S, David A (2001) Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 179:290-299
40. Magliano L, Marasco C, Fiorillo A, Malangone C, Guarneri M, Maj M, Working Group (2002) The impact of professional and social network support on the burden of families of patients with schizophrenia in Italy. Acta Psychiatr Scand 106:291-298
41. National Pharmaceutical Formulary (1998) Istituto Poligrafico e Zecca dello Stato-Rome
42. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Press, Washington DC
43. Lukoff D, Nuechterlein KH, Ventura J (1986) Manual for the expanded Brief Psychiatric Rating Scale (BPRS). Schizophr Bull 12:594-602
44. Magliano L, Fadden G, Madianos M, Caldas de Almeida JM, Held T, Guarneri M, Marasco C, Tosini P, Maj M (1998) Burden on the families of patients with schizophrenia: results of the BIOMED I study. Soc Psychiatry Psychiatr Epidemiol 33:405-412
45. World Health Organization (1988) Psychiatric disability assessment schedule (DAS), Geneva
46. Amaddeo F, Bacigalupi M, de Girolamo G, Di Munzio W, Lora A, Semisa D (1998) Attività, Interventi e Strutture del Dipartimento di Salute Mentale. Epidemiol Psichiatr Soc 7[Suppl 2]:13-30
47. Torta R (1998) Pocket edition of National Pharmaceutical Formulary - drugs for central nervous system. Centro Scientifico Editore, Turin
48. Percudani M, Barbui C (2003) Cost and outcome implications of using typical and atypical antipsychotics in ordinary practice in Italy. J Clin Psychiatry 64:1293-1299
49. Barbui C, Campomori A, Mezzalira L, Da Cas R, Garattini S (2001) Psychotropic drug use in Italy 1984-1999: the impact of a change in reimbursment status. Int Clin Psychopharmacol 16:227-233
50. Mossman D, Lehrer DS (2000) Conventional and atypical antipsychotics and the evolving standard of care. Psychiatr Serv 51:1528-1535
51. Schwartz TL, Kuhles DJ, Wade M, Masand PS (2001) Newly admitted psychiatric patient prescriptions with pharmaceutical sales visits. Ann Clin Psychiatry 13:159-162
52. Patel MX, Nicolau V, David AS (2003) Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med 33:83-89
53. Kingsbury SJ, Simpson GM (2001) Psychophamarcology: rational and irrational polypharmacy. Psychiatr Serv 52:1033-1036
54. Kingsbury SJ, Simpson GM (2002) Psychophamarcology: principles for starting, stopping or switching medications. Psychiatr Serv 53:139-140
55. Harrow M, Yonan CA, Sands JR, Marengo J (1994) Depression in schizophrenia: are neuroleptics, akinesia or anhedonia involved? Schizophr Bull 20:327-338
56. Steiner JL, Norko M, Devine S, Grottole S, Vinoski J, Griffith EE (2003) Developing ethical guidelines for pharmaceutical company support in an academic mental health center. Psychiatr Serv 54:1079-1089
57. Melander H, Ahlquist-Rastad J, Beermann B (2003) Evidence b(i)ased medicine: selective reporting from studies sponsored by pharmaceutical industry. BMJ 326:1171-1175
58. Ungvari GS, Chow LY, Chiu HF, Ng FS, Leung T (1997) Modifying psychotropic drug prescription patterns: a follow-up survey. Psychiatry Clin Neurosci 51:309-314
59. Lexchin J, Bero A, Djulbegovic B, Clark O (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326:1167-1170